Epalex is a clinical-stage pharmaceutical company focused on developing innovative therapies for migraine and epilepsy. The company addresses the significant issue of drug resistance faced by many patients who do not achieve adequate relief from existing treatments. Epalex's approach involves the exploration of new molecular strategies and unique mechanisms of action that set their drug candidates apart from current therapies. This differentiation aims to provide effective relief from migraine and epilepsy symptoms while minimizing undesirable side effects, thereby enhancing patient outcomes.

The company’s development pipeline includes EP102, designed specifically for migraine relief, and EP103, a novel antiseizure agent for epilepsy. EP102 targets hard-to-treat migraine symptoms, including nausea and sensitivity to light and sound, with a mechanism that is distinct from traditional acute migraine therapies. Meanwhile, EP103 is positioned as a broad-spectrum antiseizure treatment that could be particularly beneficial in seizure emergencies, offering a non-benzodiazepine alternative to existing treatments. Epalex's proprietary delivery technology further enhances the pharmacokinetic performance of its candidates, promising improved bioavailability and therapeutic efficacy.

United States

EpaleX is developing a novel inhaled treatment for epilepsy and migraine. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. When a seizure warning sign (aura) occurs, the patient will be able to prevent the development of a full-blown seizure through the use of a pocket nebulizer to deliver a powerful antiseizure medication that rapidly enters the brain and stops the seizure. The effect of the drug dissipates within minutes, allowing the patient to resume normal daily activity. The inhaler is also used to stop migraine attacks that are refractory to currently available migraine treatments.

Epalex

Company Details